GB2461186B - Controlled release corticosteroid compositions and methods for the treatment of otic disorders - Google Patents
Controlled release corticosteroid compositions and methods for the treatment of otic disordersInfo
- Publication number
- GB2461186B GB2461186B GB0912650A GB0912650A GB2461186B GB 2461186 B GB2461186 B GB 2461186B GB 0912650 A GB0912650 A GB 0912650A GB 0912650 A GB0912650 A GB 0912650A GB 2461186 B GB2461186 B GB 2461186B
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- methods
- controlled release
- otic disorders
- corticosteroid compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000013270 controlled release Methods 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0823378A GB2459910B (en) | 2008-04-21 | 2008-12-22 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4654308P | 2008-04-21 | 2008-04-21 | |
| US12771308P | 2008-05-14 | 2008-05-14 | |
| US8794008P | 2008-08-11 | 2008-08-11 | |
| US9524808P | 2008-09-08 | 2008-09-08 | |
| GB0823378A GB2459910B (en) | 2008-04-21 | 2008-12-22 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB0912650D0 GB0912650D0 (en) | 2009-08-26 |
| GB2461186A GB2461186A (en) | 2009-12-30 |
| GB2461186B true GB2461186B (en) | 2010-09-01 |
Family
ID=40344056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0912650A Expired - Fee Related GB2461186B (en) | 2008-04-21 | 2008-12-22 | Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| GB0823378A Expired - Fee Related GB2459910B (en) | 2008-04-21 | 2008-12-22 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0823378A Expired - Fee Related GB2459910B (en) | 2008-04-21 | 2008-12-22 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB2461186B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2461962B (en) * | 2008-07-25 | 2011-02-16 | Otonomy Inc | Slow release NMDA receptor antagonist for otic disorders |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| EP2819741B1 (en) | 2012-02-27 | 2018-03-28 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
| HK1211875A1 (en) | 2012-09-07 | 2016-06-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| WO2014144309A1 (en) | 2013-03-15 | 2014-09-18 | Oakwood Laboratories | Sustained release microspheres and method of producing the same |
| AU2016350868B2 (en) * | 2015-11-03 | 2022-03-31 | Zoetis Services Llc | Sol-gel polymer composites and uses thereof |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| US20200214976A1 (en) * | 2019-01-09 | 2020-07-09 | Spiral Therapeutics, Inc. | Self-gelling solutions for administration of therapeutics to the inner ear |
| CN110128467A (en) * | 2019-05-07 | 2019-08-16 | 天津康巢生物医药股份有限公司 | A kind of process of purification of glycerol phosphatidyl choline crude product and its obtained glycerolphosphocholine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003071986A2 (en) * | 2002-02-22 | 2003-09-04 | Control Delivery Systems, Inc. | Method for treating otic disorders |
| US20060013858A1 (en) * | 2002-10-29 | 2006-01-19 | Trune Dennis R | Fludrocortisone treatment for hearing loss |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060046970A1 (en) * | 2004-08-31 | 2006-03-02 | Insite Vision Incorporated | Topical otic compositions and methods of topical treatment of prevention of otic infections |
-
2008
- 2008-12-22 GB GB0912650A patent/GB2461186B/en not_active Expired - Fee Related
- 2008-12-22 GB GB0823378A patent/GB2459910B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003071986A2 (en) * | 2002-02-22 | 2003-09-04 | Control Delivery Systems, Inc. | Method for treating otic disorders |
| US20060013858A1 (en) * | 2002-10-29 | 2006-01-19 | Trune Dennis R | Fludrocortisone treatment for hearing loss |
Non-Patent Citations (7)
| Title |
|---|
| Biomaterials; Vol 26, pp 3311-3318 (2005). Fernandez et al. "Self-curing controlled release systems for steroids...." * |
| Chinese Medical J; Vol 120, pp 2284-2289 (2007). Sun et al. "In vitro permeability of round window membrane transforming dexamethasone...." * |
| Laryngoscope; Vol 115, pp 2016-2020 (2005). Endo et al. "Novel strategy for treatment of inner ears using a biodegradable gel" * |
| Laryngoscope; Vol 118, pp 706-711 (2008). Paulson et al. "A novel controlled local drug delivery system for inner ear disease" * |
| Lin chuang we bi yan hou tou jing wai ke za zhi; Vol 22, pp 28-31 (2008). Feng et al. "In vitro and in vivo bidegradation of sustained-release vehicle poloxamer 407 in situ gel" MEDLINE Accession number NLM18338567 * |
| Otology & Neurotology; Vol 28, pp 976-981 (2007). Lee et al. "Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel" * |
| Zhonghua yi xue za zhi; Vol 87, pp 2289-2291 (2007). Feng et al. "Effect of poloxamer 407 on cochlear morphology and hearing function..." MEDLINE Accession number NLM18001555 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0912650D0 (en) | 2009-08-26 |
| GB0823378D0 (en) | 2009-01-28 |
| GB2459910B (en) | 2010-03-31 |
| GB2459910A (en) | 2009-11-11 |
| GB2461186A (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208806A0 (en) | Controlled release corticosteroid compositions and methods for the treatment of otic disorders | |
| IL210720A0 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
| IL266471A (en) | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders | |
| HRP20182135T1 (en) | Compositions and methods for treating ige-mediated disorders | |
| IL258730A (en) | Compositions and methods for treatment of microbial disorders | |
| EP2170309A4 (en) | Methods and compositions for treating disorders | |
| GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
| GB2459910B (en) | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders | |
| IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
| PL2894165T3 (en) | Methods and compositions for treating complement-associated disorders | |
| WO2011049960A9 (en) | Compositions and methods for the treatment of sinonasal disorders | |
| EP2552433A4 (en) | Compositions and methods for the treatment of somatosensory disorders | |
| EP2293800A4 (en) | Compositions and methods for treatment of ear disorders | |
| EP2309858A4 (en) | Compositions and methods for treating inflammatory disorders | |
| IL222695A0 (en) | Methods, compositions, and kits for the treatment of matrix mineralization disorders | |
| PT2300614E (en) | Methods and compositions for treatment of mitochondrial disorders | |
| SG10201501316VA (en) | Compositions and methods for treatment of kidney disorders | |
| EP2219650A4 (en) | Compositions and methods for treating fibroproliferative disorders | |
| GB0907065D0 (en) | Anti-apoptotic composition and methods for the treatment of otic disorders | |
| GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
| IL210933A0 (en) | Compositions and methods for treating inflammatory disorders | |
| HK1160784A (en) | Methods and compositions for treating complement-associated disorders | |
| AU2007906680A0 (en) | Methods and compositions for the treatment of phosphatase-related disorders | |
| IL209658A0 (en) | Compositions and methods for treatment of ear disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20211222 |